Donghoon Lee1, Yu-Chi Hu1, Licheng Kuo1, Sadegh Alam1, Ellen Yorke1, Anyi Li1, Andreas Rimner2, Pengpeng Zhang3. 1. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, USA. 2. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, USA. 3. Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, USA. Electronic address: zhangp@mskcc.org.
Abstract
BACKGROUND AND PURPOSE: To develop a novel deep learning algorithm of sequential analysis, Seq2Seq, for predicting weekly anatomical changes of lung tumor and esophagus during definitive radiotherapy, incorporate the potential tumor shrinkage into a predictive treatment planning paradigm, and improve the therapeutic ratio. METHODS AND MATERIALS: Seq2Seq starts with the primary tumor and esophagus observed on the planning CT to predict their geometric evolution during radiotherapy on a weekly basis, and subsequently updates the predictions with new snapshots acquired via weekly CBCTs. Seq2Seq is equipped with convolutional long short term memory to analyze the spatial-temporal changes of longitudinal images, trained and validated using a dataset including sixty patients. Predictive plans were optimized according to each weekly prediction and made ready for weekly deployment to mitigate the clinical burden of online weekly replanning. RESULTS: Seq2Seq tracks structural changes well: DICE between predicted and actual weekly tumor and esophagus were (0.83 ± 0.10, 0.79 ± 0.14, 0.78 ± 0.12, 0.77 ± 0.12, 0.75 ± 0.12, 0.71 ± 0.17), and (0.72 ± 0.16, 0.73 ± 0.11, 0.75 ± 0.08, 0.74 ± 0.09, 0.72 ± 0.14, 0.71 ± 0.14), respectively, while the average Hausdorff distances were within 2 mm. Evaluating dose to the actual weekly tumor and esophagus, a 4.2 Gy reduction in esophagus mean dose while maintaining 60 Gy tumor coverage was achieved with the predictive weekly plans, compared to the plan optimized using the initial tumor and esophagus alone, primarily due to noticeable tumor shrinkage during radiotherapy. CONCLUSION: It is feasible to predict the longitudinal changes of tumor and esophagus with the Seq2Seq, which could lead to improving the efficiency and effectiveness of lung adaptive radiotherapy.
BACKGROUND AND PURPOSE: To develop a novel deep learning algorithm of sequential analysis, Seq2Seq, for predicting weekly anatomical changes of lung tumor and esophagus during definitive radiotherapy, incorporate the potential tumor shrinkage into a predictive treatment planning paradigm, and improve the therapeutic ratio. METHODS AND MATERIALS: Seq2Seq starts with the primary tumor and esophagus observed on the planning CT to predict their geometric evolution during radiotherapy on a weekly basis, and subsequently updates the predictions with new snapshots acquired via weekly CBCTs. Seq2Seq is equipped with convolutional long short term memory to analyze the spatial-temporal changes of longitudinal images, trained and validated using a dataset including sixty patients. Predictive plans were optimized according to each weekly prediction and made ready for weekly deployment to mitigate the clinical burden of online weekly replanning. RESULTS: Seq2Seq tracks structural changes well: DICE between predicted and actual weekly tumor and esophagus were (0.83 ± 0.10, 0.79 ± 0.14, 0.78 ± 0.12, 0.77 ± 0.12, 0.75 ± 0.12, 0.71 ± 0.17), and (0.72 ± 0.16, 0.73 ± 0.11, 0.75 ± 0.08, 0.74 ± 0.09, 0.72 ± 0.14, 0.71 ± 0.14), respectively, while the average Hausdorff distances were within 2 mm. Evaluating dose to the actual weekly tumor and esophagus, a 4.2 Gy reduction in esophagus mean dose while maintaining 60 Gy tumor coverage was achieved with the predictive weekly plans, compared to the plan optimized using the initial tumor and esophagus alone, primarily due to noticeable tumor shrinkage during radiotherapy. CONCLUSION: It is feasible to predict the longitudinal changes of tumor and esophagus with the Seq2Seq, which could lead to improving the efficiency and effectiveness of lung adaptive radiotherapy.
Authors: Maria Thor; Joseph O Deasy; Chen Hu; Elizabeth Gore; Voichita Bar-Ad; Clifford Robinson; Matthew Wheatley; Jung Hun Oh; Jeffrey Bogart; Yolanda I Garces; Vivek S Kavadi; Samir Narayan; Puneeth Iyengar; Jacob S Witt; James W Welsh; Cristopher D Koprowski; James M Larner; Ying Xiao; Jeffrey Bradley Journal: Clin Cancer Res Date: 2020-05-12 Impact factor: 12.531
Authors: Feng-Ming Kong; Randall K Ten Haken; Matthew Schipper; Kirk A Frey; James Hayman; Milton Gross; Nithya Ramnath; Khaled A Hassan; Martha Matuszak; Timothy Ritter; Nan Bi; Weili Wang; Mark Orringer; Kemp B Cease; Theodore S Lawrence; Gregory P Kalemkerian Journal: JAMA Oncol Date: 2017-10-01 Impact factor: 31.777
Authors: Sean L Berry; Ying Zhou; Hai Pham; Sharif Elguindi; James G Mechalakos; Margie Hunt Journal: J Appl Clin Med Phys Date: 2020-03-20 Impact factor: 2.102